Literature DB >> 36012646

Drug-Loaded Polymeric Micelles Based on Smart Biocompatible Graft Copolymers with Potential Applications for the Treatment of Glaucoma.

Manuela-Ramona Blanaru Ozturk1, Marcel Popa2,3, Delia Mihaela Rata4, Anca Niculina Cadinoiu4, Frederique Parfait5, Christelle Delaite5, Leonard Ionut Atanase3,4, Carmen Solcan6, Oana Maria Daraba4.   

Abstract

Glaucoma is the second leading cause of blindness in the world. Despite the fact that many treatments are currently available for eye diseases, the key issue that arises is the administration of drugs for long periods of time and the increased risk of inflammation, but also the high cost of eye surgery. Consequently, numerous daily administrations are required, which reduce patient compliance, and even in these conditions, the treatment of eye disease is too ineffective. Micellar polymers are core-shell nanoparticles formed by the self-assembly of block or graft copolymers in selective solvents. In the present study, polymeric micelles (PMs) were obtained by dialysis from smart biocompatible poly(ε-caprolactone)-poly(N-vinylcaprolactam-co-N-vinylpyrrolidone) [PCL-g-P(NVCL-co-NVP)] graft copolymers. Two copolymers with different molar masses were studied, and a good correlation was noted between the micellar sizes and the total degree of polymerisation (DPn) of the copolymers. The micelles formed by Cop A [PCL120-g-P(NVCL507-co-NVP128)], with the lowest total DPn, have a Z-average value of 39 nm, whereas the micellar sizes for Cop B [PCL120-g-P(NVCL1253-co-NVP139)] are around 47 nm. These PMs were further used for the encapsulation of two drugs with applications for the treatment of eye diseases. After the encapsulation of Dorzolamide, a slight increase in micellar sizes was noted, whereas the encapsulation of Indomethacin led to a decrease in these sizes. Using dynamic light scattering, it was proved that both free and drug-loaded PMs are stable for 30 days of storage at 4 °C. Moreover, in vitro biological tests demonstrated that the obtained PMs are both haemo- and cytocompatible and thus can be used for further in vivo tests. The designed micellar system proved its ability to release the encapsulated drugs in vitro, and the results obtained were validated by in vivo tests carried out on experimental animals, which proved its high effectiveness in reducing intraocular pressure.

Entities:  

Keywords:  cytotoxicity; dorzolamide; glaucoma; haemolysis; in vivo tests; indomethacin; intraocular pressure; polymeric micelles

Mesh:

Substances:

Year:  2022        PMID: 36012646      PMCID: PMC9409108          DOI: 10.3390/ijms23169382

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   6.208


  29 in total

1.  Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.

Authors:  Rajendra S Kadam; Gajanan Jadhav; Miller Ogidigben; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2011-06-14       Impact factor: 3.922

2.  The effect of topical indomethacin on acute pressure elevation of laser trabeculoplasty in capsular glaucoma.

Authors:  A Tuulonen
Journal:  Acta Ophthalmol (Copenh)       Date:  1985-04

3.  "In vitro" behaviour of aptamer-functionalized polymeric nanocapsules loaded with 5-fluorouracil for targeted therapy.

Authors:  Delia Mihaela Rață; Anca Niculina Cadinoiu; Leonard Ionut Atanase; Simona Elena Bacaita; Cristian Mihalache; Oana-Maria Daraba; Daniela Gherghel; Marcel Popa
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2019-05-30       Impact factor: 7.328

4.  Indomethacin loaded dextran stearate polymeric micelles improve adjuvant-induced arthritis in rats: design and in vivo evaluation.

Authors:  Amir Reza Abdollahi; Farzin Firouzian; Rasool Haddadi; Alireza Nourian
Journal:  Inflammopharmacology       Date:  2020-11-12       Impact factor: 4.473

5.  Effect of indomethacin on the ocular hypotensive action of timolol maleate.

Authors:  M Lichter; F Feldman; L Clark; M M Cohen
Journal:  Am J Ophthalmol       Date:  1984-07-15       Impact factor: 5.258

6.  Chitosan/hydroxyethyl cellulose inserts for sustained-release of dorzolamide for glaucoma treatment: In vitro and in vivo evaluation.

Authors:  Juçara R Franca; Giselle Foureaux; Leonardo L Fuscaldi; Tatiana G Ribeiro; Rachel O Castilho; Maria I Yoshida; Valbert N Cardoso; Simone O A Fernandes; Sebastião Cronemberger; José Carlos Nogueira; Anderson J Ferreira; André A G Faraco
Journal:  Int J Pharm       Date:  2019-09-03       Impact factor: 5.875

7.  Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System.

Authors:  P Prabhu; Kumar R Nitish; M Koland; Nm Harish; K Vijayanarayan; G Dhondge; Rn Charyulu
Journal:  J Young Pharm       Date:  2010-10

8.  Enhancement of pharmacokinetic and pharmacological behavior of ocular dorzolamide after factorial optimization of self-assembled nanostructures.

Authors:  Enas A M R Afify; Ibrahim Elsayed; Mary K Gad; Magdy I Mohamed; Abd El-Moneim M R Afify
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

9.  The impact of COVID-19 pandemic on ophthalmology services: are we ready for the aftermath?

Authors:  Darren Shu Jeng Ting; Rashmi Deshmukh; Dalia G Said; Harminder S Dua
Journal:  Ther Adv Ophthalmol       Date:  2020-10-20

10.  Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents.

Authors:  Sergio Esteban-Pérez; Vanessa Andrés-Guerrero; José Javier López-Cano; Irene Molina-Martínez; Rocio Herrero-Vanrell; Irene Bravo-Osuna
Journal:  Pharmaceutics       Date:  2020-03-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.